Patents Assigned to Amgen
  • Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
    Patent number: 11433134
    Abstract: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 6, 2022
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Jason Ko, Tiansheng Li
  • Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
    Patent number: 11427627
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 30, 2022
    Assignee: Amgen Inc.
    Inventors: Zhimei Du, Pranhitha Reddy, Randal B. Bass, Feng He, William C. Fanslow, III, Yuling Zhang, Da Ren, Randal R. Ketchem
  • Dosing of inhibitor for treatment of cancers
    Patent number: 11426404
    Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: August 30, 2022
    Assignee: Amgen Inc.
    Inventors: Haby Henary, James Russell Lipford, Victor J. Cee
  • Methods for harvesting mammalian cell cultures
    Patent number: 11427848
    Abstract: The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: August 30, 2022
    Assignee: AMGEN INC.
    Inventors: Chetan Goudar, Sean Cole, Nicole Sabo, Henry Lin, Jonathan Lull, Tharmala Tharmalingam
  • Autoinjector apparatus
    Patent number: 11419990
    Abstract: An autoinjector apparatus is disclosed which comprises a single-use cassette and an autoinjector. The cassette comprises a housing and a sleeve movably disposed in the housing. A syringe may be disposed in the sleeve and secured therein with a lock cap. The lock cap is affixed to a distal end of the sleeve and contacts the distal end of the syringe. A shield remover extends through an opening in a proximal end of the housing for removing a needle shield which covers a needle of the syringe. A cassette identification arrangement is provided on a surface of the housing to enable the autoinjector to identify the cassette. The autoinjector is provided with a detector for reading the cassette identification arrangement.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: August 23, 2022
    Assignee: AMGEN INC.
    Inventors: Michael Denzer, Robert W. Swift, Neal Johnston, Gabriele Ganzitti, Kenneth R. Ewing, Suhas Krishna
  • Pharmaceutical composition comprising bispecific antibody constructs
    Patent number: 11419933
    Abstract: The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: August 23, 2022
    Assignees: AMGEN INC., AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Sekhar Kanapuram, Ramil Latypov, Balakumar Thangaraj, Cornelius Pompe
  • BISPECIFIC BINDING CONSTRUCTS
    Publication number: 20220259329
    Abstract: New formats of bispecific binding constructs are described, as well as their methods of making. Additionally, uses in therapeutic indications are also described.
    Type: Application
    Filed: June 5, 2020
    Publication date: August 18, 2022
    Applicant: AMGEN INC.
    Inventors: Pavan GHATTYVENKATAKRISHNA, Brendan AMER
  • FORMULATIONS AND DOSAGES FOR ADMINISTERING A COMPOUND THAT INHIBITS MCL1 PROTEIN
    Publication number: 20220257607
    Abstract: Formulations of compounds of Formula I are provided as are doses and dosing regimens useful in methods of treating cancer including hematological malignances such as acute myelogenous leukemia, multiple myeloma, and non-Hodgkin's lymphoma.
    Type: Application
    Filed: April 23, 2020
    Publication date: August 18, 2022
    Applicant: AMGEN INC.
    Inventors: Ron C. KELLY, Michael T. KENNEDY, Stevedat K. LA
  • CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • Capture purification processes for proteins expressed in a non-mammalian system
    Patent number: 11407784
    Abstract: Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: August 9, 2022
    Assignee: Amgen Inc.
    Inventors: Joseph Edward Shultz, Roger Hart
  • Erenumab compositions and uses thereof
    Patent number: 11407838
    Abstract: The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Kenneth Lawson, Noel Rieder, Suminda Hapuarachchi, Jose Gregorio Ramirez
  • Electronic drug delivery device
    Patent number: 11395880
    Abstract: A drug delivery device includes a housing, a drug delivery assembly disposed within the housing along a longitudinal axis, and a cap defining a shell. At least one electronic component, a power source, and a switch assembly are at least partially disposed in and coupled to the cap. The switch assembly is movable along a plane orthogonal to the longitudinal axis of the drug delivery assembly to cause the power source to provide power to the electronic component. The device further includes an activation mechanism at least partially disposed in the cap. Upon urging the cap along the longitudinal axis in a direction away from the housing, the activation mechanism engages the switch assembly and causes the switch assembly to move, thereby causing the power source to provide power to the at least one electronic component.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: July 26, 2022
    Assignee: AMGEN INC.
    Inventors: Sung Keun Chang, Harold Dean, IV, Michael Friedman, Gordon Johnston, Neal Johnston
  • BISPECIFIC BINDING CONSTRUCTS WITH SELECTIVELY CLEAVABLE LINKERS
    Publication number: 20220227888
    Abstract: New formats of bispecific binding constructs with protease cleavable linkers are described, as well as their methods of making. Additionally, uses in therapeutic indications are also described.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 21, 2022
    Applicant: AMGEN INC.
    Inventors: Johannes BROZY, Pavan GHATTYVENKATAKRISHNA, Brendan AMER
  • Syringe adapter and guide for filling an on-body injector
    Patent number: 11389588
    Abstract: A system and a method for filling an on-body injector includes a needle of the prefilled syringe being aligned with a fill port of the on-body injector. The needle may then be inserted into a guide of a needle cover attached to the on-body injector. An adapter attached to the syringe barrel may guide the needle into a center of the bore of the guide and into the fill port of the on-body injector. The needle may be inserted into the fill port and the adapter may be mechanically coupling to the guide. After the adapter is mechanically coupled to the guide, a volume of the drug of the prefilled syringe may be dispensed into a reservoir of the on-body injector. Once the reservoir is filled to a desired amount, the needle may be removed from the fill port by decoupling the adapter from the guide.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 19, 2022
    Assignee: AMGEN INC.
    Inventor: Brian Stonecipher
  • Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors
    Patent number: 11384140
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: July 12, 2022
    Assignee: Amgen Inc.
    Inventors: Randal Robert Ketchem, Jeffrey T. McGrew, Dina A. Fomina Yadlin
  • Testing assemblies and testing methods for drug delivery devices
    Patent number: 11385140
    Abstract: A testing assembly for a drug delivery device is disclosed. The testing assembly can include a pressure vessel having a sealed pressure chamber that is configured to be pressurized to a predetermined pressure. The pressure vessel further defines an injection opening extending from an exterior thereof to the pressure chamber. A pierceable barrier extends over and seals the injection opening. The testing assembly further includes a measurement device disposed within the pressure chamber and a container aligned with the injection opening, such that the container is configured to collect a dose of a drug delivered via a drug delivery device through the pierceable barrier and the measurement device is configured to measure the dose of the drug.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: July 12, 2022
    Assignee: AMGEN INC.
    Inventors: Yasaman Damestani, Bryton De Guia, Martin Hering, Matthew Wayne Janke, Jerome Olivas, David Plescia, Brendan Smyth, Guojie Song
  • Handheld drug delivery device
    Patent number: D958329
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 19, 2022
    Assignee: AMGEN INC.
    Inventors: Dylan Bourelle, Eric Ang-Schmid, Jakob Halkjaer Pedersen, Joshua Jay Dudman
  • Handheld drug delivery device
    Patent number: D962423
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: August 30, 2022
    Assignee: AMGEN INC.
    Inventors: Matias Melander, Bjarke Lykke Ludvig Hooge, Christian Plambech, Dylan Bourelle, Jakob Halkjaer Pedersen, Joshua J. Dudman, Emil Spork
  • Vial sleeve
    Patent number: D962472
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: August 30, 2022
    Assignee: AMGEN INC.
    Inventors: Anthony Bantug, Wael Mismar, Kenneth Tan, Tark Abed, Justin Allen Marsh, Mario Bogdan, Scott Comiso
  • Infusion pump
    Patent number: D963158
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: September 6, 2022
    Assignee: AMGEN INC.
    Inventors: Scott R. Gibson, Mehran Mojarrad, Paul Daniel Faucher